Robert W. Baird Lowers Cellectis (NASDAQ:CLLS) Price Target to $8.00

Cellectis (NASDAQ:CLLS) had its target price dropped by Robert W. Baird from $10.00 to $8.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Robert W. Baird’s target price suggests a potential upside of 337.16% from the stock’s previous close.

A number of other brokerages have also recently weighed in on CLLS. Barclays assumed coverage on shares of Cellectis in a research note on Thursday, May 28th. They set an “overweight” rating and a $9.00 price objective for the company. Citizens Jmp reiterated a “market perform” rating on shares of Cellectis in a report on Tuesday. Wells Fargo & Company dropped their price target on Cellectis from $4.00 to $3.00 and set an “equal weight” rating for the company in a research report on Tuesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cellectis in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $7.00.

Cellectis Price Performance

Cellectis stock opened at $1.83 on Tuesday. The firm has a market capitalization of $183.62 million, a PE ratio of -2.82 and a beta of 2.92. Cellectis has a 52 week low of $1.75 and a 52 week high of $5.48. The firm’s 50-day simple moving average is $3.00 and its 200 day simple moving average is $3.34. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 1.61.

Cellectis (NASDAQ:CLLS) last posted its earnings results on Friday, August 7th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.04. The firm had revenue of $6.90 million during the quarter, compared to the consensus estimate of $11.05 million. Cellectis had a negative net margin of 102.34% and a negative return on equity of 94.19%.

Institutional Trading of Cellectis

A hedge fund recently bought a new position in Cellectis stock. Lido Advisors LLC bought a new position in Cellectis S.A. (NASDAQ:CLLS) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 10,094 shares of the biotechnology company’s stock, valued at approximately $32,000. 63.90% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Cellectis

Here are the key news stories impacting Cellectis this week:

• Positive Sentiment: Cellectis plans to focus on in vivo gene-editing treatments for chronic diseases, a strategy that could create a more scalable platform and support longer-lasting therapies. Cellectis Announces Strategic Transformation to In Vivo Gene-Editing Company
• Neutral Sentiment: Citizens JMP reaffirmed its “market perform” rating, indicating limited near-term conviction while the company undergoes the transformation. CLLS Stock Heads for 14-Month Low After 40% Rout
• Negative Sentiment: Cellectis is exiting development of its lasme-cel and eti-cel programs as part of the pivot. Abandoning these cancer programs removes existing pipeline catalysts and contributed to the selloff. Cellectis Announces In Vivo Gene-Editing Transformation
• Negative Sentiment: Citizens JMP flagged delayed catalysts following the cancer-pipeline pivot, suggesting investors may face a longer wait for meaningful clinical or commercial progress. Delayed Cellectis Catalysts After Cancer Pipeline Pivot
• Negative Sentiment: The stock fell below its 50-day moving average and approached a 14-month low, signaling deteriorating momentum and potentially encouraging additional technical selling. Cellectis Share Price Crosses Below Fifty-Day Moving Average

About Cellectis

Cellectis SA (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing gene-edited, allogeneic T-cell therapies for cancer. The company uses its gene-editing technologies, including TALEN-based technology, to modify immune cells so they can be manufactured in advance and potentially administered to multiple patients rather than produced individually.

Cellectis’ product candidates are designed primarily as chimeric antigen receptor T-cell (CAR-T) therapies for hematologic malignancies and other serious diseases.